The discovery of EGFR mutations and the advent of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of metastatic NSCLC has dramatically changed the prognosis of selected patients and become an important milestone in NSCLC targeted therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.